COHERUS ONCOLOGY INC

Coherus CFO’s strategic option sales reveal confidence in a new, lower‑exercise price, boosting employee retention while preserving long‑term upside for investors.

Coherus Oncology CEO buys 375,000 shares at zero cost and locks in 750,000 options, boosting investor confidence in its oncology biosimilar growth strategy.

Coherus insider sales show routine tax‑planning, not a price collapse: CFO’s 1,715‑share sell at $1.55 and CEO’s 11,839 shares highlight short‑term liquidity moves, but fundamentals remain solid and the company stays a low‑beta, value‑oriented biote…